Molecular response to aromatase inhibitor treatment in primary breast cancer

Alan Mackay, Ander Urruticoechea, J Michael Dixon, Tim Dexter, Kerry Fenwick, Alan Ashworth, Suzanne Drury, Alexey Larionov, Oliver Young, Sharon White, William R Miller, Dean B Evans, Mitch Dowsett

Research output: Contribution to journalArticlepeer-review


Aromatase inhibitors such as anastrozole and letrozole are highly effective suppressants of estrogen synthesis in postmenopausal women and are the most effective endocrine treatments for hormone receptor positive breast cancer in such women. Little is known of the molecular effects of these agents on human breast carcinomas in vivo.
Original languageEnglish
Pages (from-to)R37
JournalBreast Cancer Research
Issue number3
Publication statusPublished - 2007


  • Antineoplastic Agents, Hormonal
  • Aromatase Inhibitors
  • Breast Neoplasms
  • Combined Modality Therapy
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Nitriles
  • Polymerase Chain Reaction
  • Postmenopause
  • Receptors, Estrogen
  • Triazoles
  • Up-Regulation

Fingerprint Dive into the research topics of 'Molecular response to aromatase inhibitor treatment in primary breast cancer'. Together they form a unique fingerprint.

Cite this